Vertex Pharmaceuticals (VRTX) Capital Expenditures Growth (1y) (2010 - 2026)
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 22,433.30% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -73.62% |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | -34.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.99% |
| Mar 31, 2026 | 227.76% |
| Dec 31, 2025 | 61.34% |
| Sep 30, 2025 | 50.37% |
| Jun 30, 2025 | 111.16% |
| Mar 31, 2025 | -40.50% |
| Dec 31, 2024 | 59.38% |
| Sep 30, 2024 | 66.75% |
| Jun 30, 2024 | 15.77% |
| Mar 31, 2024 | 62.47% |
| Dec 31, 2023 | 72.92% |
| Sep 30, 2023 | -25.09% |
| Jun 30, 2023 | 11.82% |
| Mar 31, 2023 | -33.81% |
| Dec 31, 2022 | -45.63% |
| Sep 30, 2022 | 3.44% |
| Jun 30, 2022 | 6.81% |
| Mar 31, 2022 | -10.30% |
| Dec 31, 2021 | 29.58% |
| Sep 30, 2021 | -70.02% |